Global Anti-Asthmatics And Copd Drugs Market Size 2024, Forecast To 2033
11 Mar, 2024
The anti-asthmatics and COPD drugs market has experienced robust growth, escalating from $76.16 billion in 2023 to $81.41 billion in 2024, with a compound annual growth rate (CAGR) of 6.9%. This growth in the historic period is attributed to factors such as an increase in respiratory diseases, higher tobacco smoking rates, global warming effects, a growing geriatric population, emerging markets, and new methods for drug discovery. Moving into the future, the market is poised for continued expansion, reaching $104.1 billion in 2028 at a CAGR of 6.3%. This growth is expected due to the rising popularity of e-cigarettes/vaping, increasing obesity rates, technological advancements, and the use of these drugs in treating COVID-19 patients, accompanied by trends like developing probiotic drugs for asthma, launching innovative products, and investing in bioelectric medicines.
Global Anti-Asthmatics And COPD Drugs Market Key Driver
The Asthma and COPD drugs market is influenced by modifiable risk factors, including smoking, lack of physical exercise, and unhealthy eating habits. Although there is a decreasing global trend in smoking prevalence, developing countries such as China, India, Indonesia, and Nigeria are experiencing an increase in smoking prevalence. For example, Indonesia is expected to witness a rise of 24 million tobacco smokers, and Nigeria is anticipated to see an increase of 7 million smokers by 2025. Additionally, more than 40% of global cigarette consumption is concentrated in China. The consumption of fats, particularly saturated fatty acids, which is a risk factor for Asthma and COPD, is higher in high-income countries like the USA and Europe. According to the World Health Organization (WHO), developed countries derive over 35% of their total energy requirement from fats, compared to less than 20% in low-income countries and less than 25% in lower-middle-income countries.
Get A Free Sample Of The Global Anti-Asthmatics And COPD Drugs Market ReportGlobal Anti-Asthmatics And COPD Drugs Market Segments
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
By Geography:The regions covered in the anti-asthmatics and copd drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
North America was the largest region in the anti-asthmatics and COPD drugs market in 2023. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and copd drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Anti-Asthmatics And COPD Drugs Industry Players
GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, GSK, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Cipla Medpro South Africa (Pty) Limited, Aspen Nigeria
Get The Full Global Anti-Asthmatics And COPD Drugs Market Report
Anti-Asthmatics And COPD Drugs Market Overview
Anti-asthmatic and chronic obstructive pulmonary disease refers to drugs that are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.
Anti-Asthmatics And COPD Drugs Global Market Report 2023 provides data on the global anti-asthmatics and copd drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The anti-asthmatics and copd drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.